Drug intelligence / Profile preview

DXC019

Development stage: Preclinical
Lead developer: Hangzhou DAC Biotech
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DXC019 is a preclinical antibody-drug conjugate (ADC) being developed by Hangzhou DAC Biotech for the treatment of solid tumors. As part of DAC Biotech's proprietary ADC platform, DXC019 is designed to deliver a cytotoxic payload directly to tumor cells by targeting a specific, though currently undisclosed, cell-surface antigen. The company utilizes specialized linker-payload technologies to enhance the stability and efficacy of its conjugates. DXC019 is currently undergoing preclinical evaluation to determine its safety and anti-tumor activity before potentially advancing to clinical trials.

Beyond the preview

Go deeper on DXC019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXC019.

Explore the full profile